GlaxoSmithKline’s Advair Poses Generic Hurdle

WSJ -- With a key patent on its top-selling asthma drug Advair expiring next year, GlaxoSmithKline PLC should be bracing for a steep decline in Advair sales as low-cost generics rush in to claim a big chunk of the market.